Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with daraxonrasib improving survival in pancreatic cancer. Major pharma companies like Merck, Roche, and Bristol Myers Squibb are potential acquirers due to the scarcity of advanced RAS therapies. Key upcoming events include FDA decisions and clinical trial readouts, which could further impact the stock's outlook.
Pfizer shares trade at $28.77 with a 5.91% dividend yield and a 12-month price target of $32.72, implying 13.84% upside. The company reported strong Q2 2026 results, raised revenue guidance, and has a promising pipeline including Padcev and Metsera o...
Pfizer's stock has declined nearly 20% over five years, pushing its dividend yield to around 6%. Despite this, the company continues to pay a steady $0.43 quarterly dividend, supported by earnings that cover the payout but with tight cash flow margin...
